CTU vs IVU Scans for Bladder Cancer

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: M.D. Anderson Cancer Center

Disqualifiers: Elevated creatinine, Contrast allergy, Ureteral stint, Women childbearing, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

133 Participants Needed

Trial Summary

What is the purpose of this trial?

The goal of this clinical research study is to use computed tomography urography (CTU) scans and intravenous urography (IVU) scans to check the status of urothelial cancer, in order to try to learn the level of effectiveness of possibly using CTU by itself in future patients.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment CTU vs IVU Scans for Bladder Cancer?

Computed tomography urography (CTU) is widely used for evaluating bladder cancer because it provides a fast and comprehensive view of the urinary tract in one exam, making it more effective than intravenous urography (IVU) for initial evaluations. ^{1 2 3 4 5}

Is CTU or IVU safe for humans?

CTU and IVU are generally safe, but CTU involves higher radiation exposure and the use of iodinated contrast, which can have serious side effects. IVU is less costly and involves less radiation, but may not be as effective in detecting certain conditions. ^{1 2 3 6 7}

How does CTU differ from IVU in treating bladder cancer?

Computed Tomography Urography (CTU) is unique because it provides a fast and comprehensive evaluation of the urinary tract in a single exam, which is more accurate than Intravenous Urography (IVU) and does not require bowel preparation. However, CTU has a higher radiation dose compared to IVU, although efforts are being made to reduce this with low-dose protocols. ^{4 8 9 10 11}

Research Team

Chaan Ng, MD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for adults over 18 with confirmed urothelial cancer, including those who've had bladder tumors of Stage T3 or higher, cystectomies for bladder cancer, or upper tract TCC. Participants must consent and be referred for CTU as part of routine care. It's not suitable for individuals with high serum creatinine levels (>2), contrast media allergies, women who could become pregnant, or those who have had a ureteral stint placed or removed within six weeks.

Inclusion Criteria

I had surgery to remove my bladder due to cancer.

I am scheduled for IVU with digital tomosynthesis and a CT scan as part of my routine care.

I have cancer in the upper part of my urinary system.

Exclusion Criteria

I am a woman who could become pregnant.

I am allergic to IV dye used in CT scans.

I have had a ureteral stent placed or removed in the last six weeks.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Diagnostic Procedure

Participants undergo CTU and IVU procedures to assess the technical efficacy of CTU compared to IVU

1 day

1 visit (in-person)

Follow-up

Participants' images are reviewed a second time by additional radiologists to compare findings

3 months

Treatment Details

Interventions

• Computed Tomography Urography (CTU)
• Intravenous Urography (IVU)

Trial Overview The study compares the effectiveness of Computed Tomography Urography (CTU) versus Intravenous Urography (IVU) in evaluating urothelial cancers. The aim is to determine if CTU can be used alone to assess these cancers effectively in future patients.

Participant Groups

Group I: CTU + IVU Experimental Treatment 2 Interventions

CTU = Computed Tomography Urography + IVU = Intravenous Urography

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

GE Healthcare

Industry Sponsor

Trials

307

Recruited

634,000+

Fotis Vlachos

GE Healthcare

Chief Marketing Officer since 2024

PhD in Molecular Biology and Biochemistry from the University of Massachusetts, MBA from the Wharton School of the University of Pennsylvania

Peter J. Arduini

GE Healthcare

Chief Executive Officer since 2022

MBA from Northwestern University, BSc in Marketing from Susquehanna University

References

1. England pubmed.ncbi.nlm.nih.gov

Limited significance of routine excretory urography in the follow-up of patients with superficial bladder cancer after transurethral resection. [2019]

2. United States pubmed.ncbi.nlm.nih.gov

Bladder cancer diagnosis: the role of CT urography. [2022]

3. England pubmed.ncbi.nlm.nih.gov

Contrast enhancement in bladder tumors examined with CT urography using traditional scan phases. [2022]

4. United States pubmed.ncbi.nlm.nih.gov

Radiologic imaging of patients with bladder cancer. [2012]

5. England pubmed.ncbi.nlm.nih.gov

Evaluation of multidetector computed tomography urography and ultrasonography for diagnosing bladder cancer. [2019]

6. Ireland pubmed.ncbi.nlm.nih.gov

Performance of computed tomographic urography in diagnosis of upper urinary tract urothelial carcinoma, in patients presenting with hematuria: Systematic review and meta-analysis. [2022]

7. England pubmed.ncbi.nlm.nih.gov

Intravenous urography in urinary tract surveillance in carcinoma of the bladder. [2019]

8. China pubmed.ncbi.nlm.nih.gov

Practical value of intravenous urography combined with add-on CT in diagnosing ureteral abnormalities. [2016]

9. Spain pubmed.ncbi.nlm.nih.gov

[Intravesical echography. I. Anatomical correlation]. [2016]

10. Italy pubmed.ncbi.nlm.nih.gov

CT urography: the end of IVU? [2021]

11. United States pubmed.ncbi.nlm.nih.gov

Acute flank pain: comparison of non-contrast-enhanced CT and intravenous urography. [2022]